Overcoming Resistance Mechanisms and Addressing Unmet Needs
Panelists discuss how overcoming resistance to EGFR TKIs requires next-generation inhibitors and more individualized treatment strategies.
Understanding EGFR Mutations and First-Line Treatment
Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine.
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
Zongertinib shows promising results in HER2-mutant NSCLC, offering high response rates and improved quality of life with minimal toxicity.
